Inghams is Australia and New Zealand's largest vertically integrated poultry producer, supplying supermarkets, quick-service restaurants, and wholesale customers from farm to shelf. At A$2.11 against a fair value of A$3.38, the stock is undervalued by 60%. The key driver is a temporary margin collapse caused by identifiable, quantified costs that are already reversing — not a structural deterioration in the business.

This stock fits value investors best. The business is structurally sound — a duopoly protected by biosecurity barriers with a 40-year operating history — but the market is pricing it as though the current margin trough is permanent. Investors willing to wait 12–18 months for operational evidence can access a 60% gap to fair value with a specific catalyst date and positive free cash flow throughout the recovery.

Inghams breeds, processes, and distributes chicken and turkey across Australia and New Zealand, supplying major retailers, quick-service restaurant chains, and wholesale markets. It controls roughly 40–43% of the Australian market and more than half of the New Zealand market, making it the dominant player in both countries. Revenue of A$3.15 billion is stable; the business earns its money on the margin between feed costs, processing labour, and the price it charges customers.

The first half of FY26 was painful. EBITDA margins fell to around 5% — well below the 7.4–7.5% delivered in the prior two years — as three costs hit simultaneously: a Woolworths volume loss required expensive channel rebuilding, an inventory overhang absorbed $16.7 million in excess costs, and grower contract transitions added further friction. The good news is that $31.3 million of these costs have been identified line by line as non-recurring. The inventory was cleared by December 2025. Production has normalised. And the New Zealand business, running identical poultry operations at 8.8–10.3% EBITDA margins, confirms what Australian margins can return to.

The investment case rests on one question: is the margin collapse cyclical or structural? We assess it as 70% cyclical. At A$2.11 versus fair value of A$3.38, the stock is undervalued by 60%.

What happened?

The first half of FY26 delivered EBITDA of approximately A$81 million — roughly half the run-rate needed to hit full-year guidance of A$180–200 million. The culprit was a simultaneous collision of transitory costs: channel rebuilding after the Woolworths contract loss, an inventory overhang from production miscalibration, and grower transition friction. The business did not lose market share; it lost margin while reorganising its supply chain.

What's next?

The second half of FY26 needs to deliver roughly A$104 million in EBITDA to reach the midpoint of guidance — a 30% step-up from the first half. That is achievable if the identified cost reversals materialise as expected: inventory costs have already cleared, production efficiency is recovering, and a A$24.9 million feed cost tailwind remains intact. Non-Woolworths retail volumes grew 16.6% in the first half, confirming channel diversification is working.

The cleaner story begins in FY27, when the transitory costs are fully behind the business and the A$60–80 million cost-out programme starts contributing. By FY28, we estimate margins returning to 7.0% and ROIC recovering toward 20%. The August 2026 full-year result is the single most important data point — it will either confirm the recovery thesis or force a reassessment of how much of the margin collapse is permanent.

The fair value of A$3.38 blends three methods: a probability-weighted DCF (51% weight, A$4.02), peer trading multiples (38% weight, A$3.30), and book value (11% weight, A$0.69). The wide confidence interval — A$1.86 to A$4.90 — reflects genuine uncertainty about whether the margin recovery is cyclical or structural. The market is not obviously wrong: at a 10% discount rate rather than our 7.1%, the base-case DCF produces A$2.15, almost exactly the current price. The disagreement is about risk premium, not fundamentals.

The single biggest risk is a second-half execution failure. The business needs roughly A$104 million of EBITDA in the second half of FY26 to hit guidance — and a new CEO with less than a year on the job is running the turnaround. If that target is missed, net debt to EBITDA stays above 2.4x into the December 2026 covenant test, constraining the balance sheet and undermining the recovery timeline. In the severe scenario — covenant stress and a dilutive equity raise — fair value falls to A$1.12, representing a 47% loss from current prices at a 10% assigned probability.